The Lancet November 20, 2026

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial

SERVAL Trial Investigators (Umberto d'Alessandro et al.)

Bottom Line

Seasonal mass vaccination of entire communities with the R21/Matrix-M malaria vaccine safely and significantly reduced malaria prevalence at peak transmission in both low-to-moderate and high-transmission settings in West Africa.

Key Findings

1. In The Gambia (low-to-moderate transmission), seasonal mass vaccination with R21 reduced the odds of malaria infection by 70% (adjusted odds ratio 0.30 [95% CI 0.20-0.44]; p<0.0001).
2. In The Gambia, the reduction in malaria prevalence was observed across all age groups.
3. In Burkina Faso (intense seasonal transmission), seasonal mass vaccination reduced the odds of malaria infection by 25% (adjusted odds ratio 0.75 [95% CI 0.58-0.98]; p=0.036), with the largest effect seen in children younger than 5 years.
4. The vaccine demonstrated a favorable safety profile; adverse events were reported in 13.5% (581/4,311) of recipients in The Gambia and 11.3% (705/6,235) in Burkina Faso.
5. Among 69 overall serious adverse events, only one (a febrile convulsion in an 8-year-old female after the second dose in The Gambia) was considered related to vaccination.
6. Vaccination coverage was moderate: 59.5% of eligible residents in The Gambia and 65.3% in Burkina Faso received all three doses of the vaccine.

Study Design

Design
Cluster-Randomized Trial
Open-Label
Sample
54 clusters
Patients
Duration
6 mo
Median
Setting
Gambia and Burkina Faso
Population Residents aged 5 months and older residing in 54 medium-sized villages in The Gambia (low-to-moderate seasonal transmission) and Burkina Faso (intense seasonal transmission).
Intervention Seasonal mass vaccination (SMV) delivered as three monthly doses of R21/Matrix-M (5 μg R21 for <15 years; 10 μg for ≥15 years, combined with 50 μg Matrix-M) prior to peak transmission, alongside national standard malaria control interventions.
Comparator No seasonal mass vaccination (national standard malaria control interventions only).
Outcome Malaria prevalence at peak transmission (defined as the proportion of participants with Plasmodium falciparum infection assessed by quantitative PCR).

Study Limitations

• The open-label design introduces a risk of bias, though the primary endpoint was objectively assessed via quantitative PCR.
• Vaccine uptake varied and adherence to the full three-dose regimen was suboptimal (approx. 60-65%), which may underestimate the true biological efficacy of the vaccine or highlight potential real-world logistical challenges for mass vaccination campaigns.
• The short duration of follow-up (cross-sectional survey at a single peak transmission point) limits the ability to assess the durability of community-level protection beyond a single malaria season.
• The cluster-randomised design, while necessary for mass community interventions, inherently carries a higher risk of baseline imbalances between study arms compared to individual randomisation.

Clinical Significance

This landmark trial expands the utility of the R21/Matrix-M vaccine beyond the WHO-recommended routine immunization of infants, demonstrating that whole-population seasonal mass vaccination can serve as a potent new tool for malaria control. Integrating this approach with existing measures has the potential to dramatically accelerate progress towards elimination in low-to-moderate transmission zones (like The Gambia) while providing a critical reduction in disease burden in high-transmission areas (like Burkina Faso).

Historical Context

Despite the widespread rollout of seasonal malaria chemoprevention and insecticide-treated bed nets, global progress against malaria has stagnated over the past decade, missing key targets set by the WHO Global Technical Strategy for Malaria 2016–2030. While vaccines like RTS,S and R21 were historically developed and approved to protect young children—who suffer the highest mortality—older children and asymptomatic adults remain significant reservoirs for Plasmodium falciparum transmission. The SERVAL trial provides the first large-scale evidence that extending vaccination to the entire community ahead of the rainy season can meaningfully disrupt transmission dynamics.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

The R21 vaccine targets the circumsporozoite protein (CSP) of Plasmodium falciparum. Based on the parasite's life cycle, at what stage of infection does this vaccine primarily exert its protective effect, and why is the inclusion of the Matrix-M adjuvant critical for achieving this clinical efficacy?

Key Response

CSP is the dominant surface protein of the sporozoite stage, which is injected into the human host by the Anopheles mosquito. The vaccine works by neutralizing sporozoites before they can invade hepatocytes, thereby preventing the subsequent symptomatic blood-stage infection. The Matrix-M adjuvant (a saponin-based adjuvant) is essential because it potently stimulates both cellular and humoral immune responses, generating the exceptionally high antibody titers required to intercept and clear sporozoites during their brief transit from the skin to the liver.

Resident
Resident

In regions with highly seasonal malaria transmission, how does seasonal mass vaccination with R21/Matrix-M theoretically compare with, or complement, existing Seasonal Malaria Chemoprevention (SMC) in terms of population coverage, resistance profiles, and the prevention of clinical disease?

Key Response

SMC involves the monthly administration of antimalarials (e.g., sulfadoxine-pyrimethamine plus amodiaquine) to vulnerable children during the rainy season. While SMC is highly effective, it is limited by adherence to monthly dosing and the growing threat of antimalarial drug resistance. Seasonal mass vaccination offers potentially longer-lasting immunity with fewer doses and circumvents parasite drug resistance mechanisms. Understanding this distinction helps clinicians and public health officers integrate these interventions, as combining vaccines with SMC may provide synergistic protection and lower clinical disease burden more effectively than either strategy alone.

Fellow
Fellow

This trial evaluated the mass vaccination of entire communities rather than just age-based pediatric cohorts. From an infectious disease transmission dynamics perspective, what is the rationale for targeting all age groups, and how might this strategy impact the basic reproduction number (R0) of Plasmodium falciparum in these settings?

Key Response

While severe malaria predominantly affects young children, older children and asymptomatic adults serve as significant reservoirs for gametocytes, which sustain mosquito infection rates. Mass community vaccination aims to reduce the overall human infectious reservoir, thereby lowering transmission intensity (and R0) for the entire community. This provides indirect protection (herd immunity) that age-based pediatric vaccination alone cannot achieve, which is a critical consideration for subspecialists focused on malaria eradication rather than just disease control.

Attending
Attending

Given the logistical complexities of cold-chain maintenance and mass campaign execution in resource-limited settings, how should clinical and public health leaders weigh the upfront operational costs of community-wide R21/Matrix-M vaccination against the long-term clinical and economic benefits observed during peak transmission seasons?

Key Response

Attendings must consider the macro-level impact of community interventions. While mass vaccination campaigns require significant immediate resources for staffing, logistics, and community sensitization, they can drastically decrease peak-season pediatric ward overcrowding, reduce cases of severe anemia and cerebral malaria, and ultimately lower overall healthcare system costs. This represents a highly cost-effective paradigm shift, moving the clinical focus from seasonal crisis management to robust, proactive population health protection.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The study utilized an open-label, cluster-randomised design. What are the primary methodological threats to validity introduced by the open-label nature when evaluating outcomes like 'malaria prevalence' or 'clinical episodes', and how does cluster randomization necessitate specific statistical adjustments to prevent Type I errors?

Key Response

Open-label designs can introduce significant behavioral biases; for example, control communities aware they did not receive the vaccine might alter their health-seeking behavior or increase their use of bed nets, potentially diluting the observed intervention effect. Additionally, cluster randomization requires adjusting for intra-cluster correlation (ICC) using generalized linear mixed models or generalized estimating equations. Individuals within the same cluster often share similar exposures and behaviors; failing to account for this non-independence artificially narrows confidence intervals and inflates the risk of false-positive findings.

Journal Editor
Journal Editor

As a peer reviewer, a major concern in trials of seasonal interventions is the sustainability of the effect and the potential for confounding by baseline transmission intensity. Did the study design incorporate sufficient follow-up to assess the 'rebound effect' in subsequent seasons, and how might pooling data from both low-transmission (The Gambia) and high-transmission (Burkina Faso) settings mask differential vaccine efficacy?

Key Response

A critical editorial focus is whether short-term gains come at a long-term cost. Preventing infection in one season might delay the acquisition of natural immunity, potentially leading to severe rebound malaria if vaccine efficacy wanes rapidly in subsequent years. Furthermore, analyzing pooled data from disparate transmission settings is methodologically risky; high exposure in Burkina Faso could rapidly overwhelm vaccine-induced antibody titers, whereas low exposure in The Gambia might show prolonged efficacy. A rigorous review would demand stratified analyses and extended longitudinal follow-up to address these threats to external validity.

Guideline Committee
Guideline Committee

The current WHO guidelines strongly recommend the R21/Matrix-M vaccine for children living in regions with moderate-to-high P. falciparum transmission. Based on the findings of this community-wide mass vaccination trial, what specific criteria and evidence thresholds must be met to justify expanding the WHO recommendation from targeted pediatric age groups to seasonal vaccination for all age groups?

Key Response

Current WHO guidelines restrict malaria vaccines to infants and young children (typically starting at 5 months of age) primarily to prevent severe disease and death in the most vulnerable demographic. To update these guidelines for community-wide mass vaccination, the committee requires robust evidence demonstrating significant transmission-blocking effects (herd immunity) that justify the massive financial burden and supply chain diversion of vaccinating adults. The evidence must show that vaccinating older, largely immune populations is cost-effective, does not exacerbate global vaccine shortages for children, and significantly reduces the overall community transmission beyond what is achieved by targeted pediatric vaccination combined with vector control.

Clinical Landscape

Noteworthy Related Trials

2015

RTS,S Clinical Trials Partnership Phase 3 Trial

n = 15,459 · Lancet

Tested

RTS,S/AS01 malaria vaccine

Population

African infants and children aged 6-12 weeks and 5-17 months

Comparator

Control vaccine (rabies or meningococcal C)

Endpoint

Clinical malaria episodes

Key result: Vaccine efficacy against clinical malaria was 36.3 percent in children and 25.9 percent in infants over 48 months of follow-up.
2021

R21/Matrix-M Phase 2b Trial

n = 450 · Lancet

Tested

R21/Matrix-M malaria vaccine

Population

Children aged 5-17 months in Burkina Faso

Comparator

Rabies vaccine (control)

Endpoint

Time to first episode of clinical malaria

Key result: Demonstrated 77 percent efficacy against clinical malaria over 12 months, making it the first vaccine to meet the WHO 75 percent efficacy goal.
2021

SMC and RTS,S/AS01 Combination Trial

n = 6,861 · NEJM

Tested

RTS,S/AS01 vaccine combined with seasonal malaria chemoprevention (SMC)

Population

Children aged 5-17 months in Burkina Faso and Mali

Comparator

SMC alone and RTS,S/AS01 alone

Endpoint

Incidence of clinical malaria, hospital admissions, and deaths

Key result: The combination of the RTS,S/AS01 vaccine and SMC was significantly more effective than either intervention alone in preventing clinical and severe malaria.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑